Andrew L. Pecora, MD, FACP CPE

//Andrew L. Pecora, MD, FACP CPE

Andrew L. Pecora, MD, FACP CPE

Dr. Pecora MD, FACP CPE, is the founder and executive chairman of COTA, Inc., and vice president cancer services and chief innovations officer at Hackensack University Medical Center and Founder of Regional Cancer Care Associates.  In 2004, Dr. Pecora was promoted to professor of medicine, University of Medicine and Dentistry of New Jersey – New Jersey Medical School, and in 2013 to professor of oncology and medicine, Georgetown University.

Dr. Pecora is a diplomate of the American Board of Internal Medicine, subspecialty of hematology and subspecialty of oncology. Dr. Pecora co-founded and served as chairman and chief Therapy, LLC, a company focused on facilitating the transfer of laboratory breakthrough to clinical application and practice in cell therapies. He also co-founded and served as chairman of Amorcyte, Inc., a biotechnology company developing cell therapies for cardiovascular disease. Dr. Pecora founded COTA, a healthcare software analytic company focused on enabling value-based care delivery and serves as executive chairman.

Dr. Pecora has been involved in numerous research projects in an effort to improve the outcomes of patients with cancer. His work included leading the international effort to standardize CD34 enumeration and working to develop the production of stem cell products that are free of contamination malignant cells using technologies including CD34 selection and ex vivo expansion. In addition, he led the first effort to assess in humans, the safety and efficacy of oncolytic viruses administered parentally. Dr. Pecora hold over 80 national and international patents covering the composition and use of bone marrow derived cells for treating cardiovascular disease and in data analytics. Dr. Pecora has led several national trials in the field of transplantation and has published numerous peer-reviewed articles and abstracts and has presented at many national and international scientific meetings.